Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Verschueren

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
Annals of the Rheumatic Diseases|April 8, 2026
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritisFaidra Laskou, Victoria Konzett, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|June 2, 2026
Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task ForceVictoria Konzett, Faidra Laskou, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|April 17, 2026
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritisVictoria Konzett, Faidra Laskou, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|July 20, 2016
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trialPatrick Verschueren, Diederik De Cock, Luk Corluy, et al.
Arthritis Research & Therapy|April 19, 2015
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trialPatrick Verschueren, Diederik De Cock, Luk Corluy, et al.
RMD Open|August 8, 2024
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trialDelphine Bertrand, Johan Joly, Barbara Neerinckx, et al.
Annals of the Rheumatic Diseases|June 13, 2022
Standardisation of ACPA tests: evaluation of a new candidate reference preparationLieve Van Hoovels, Lucy Studholme, Bert Vander Cruyssen, et al.
RMD Open|March 24, 2022
Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test resultsLieve Van Hoovels, Bert Vander Cruyssen, Daniela Sieghart, et al.
Clinical Chemistry and Laboratory Medicine|July 5, 2022
IgA rheumatoid factor in rheumatoid arthritisLieve Van Hoovels, Bert Vander Cruyssen, Daniela Sieghart, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|April 8, 2026
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritisFaidra Laskou, Victoria Konzett, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|June 2, 2026
Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task ForceVictoria Konzett, Faidra Laskou, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|April 17, 2026
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritisVictoria Konzett, Faidra Laskou, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|July 20, 2016
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trialPatrick Verschueren, Diederik De Cock, Luk Corluy, et al.
Arthritis Research & Therapy|April 19, 2015
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trialPatrick Verschueren, Diederik De Cock, Luk Corluy, et al.
RMD Open|August 8, 2024
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trialDelphine Bertrand, Johan Joly, Barbara Neerinckx, et al.
Annals of the Rheumatic Diseases|June 13, 2022
Standardisation of ACPA tests: evaluation of a new candidate reference preparationLieve Van Hoovels, Lucy Studholme, Bert Vander Cruyssen, et al.
RMD Open|March 24, 2022
Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test resultsLieve Van Hoovels, Bert Vander Cruyssen, Daniela Sieghart, et al.
Clinical Chemistry and Laboratory Medicine|July 5, 2022
IgA rheumatoid factor in rheumatoid arthritisLieve Van Hoovels, Bert Vander Cruyssen, Daniela Sieghart, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Pageof 16